We are monitoring the impact of COVID-19 on MEA Infectious Disease Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 1250
Share on
Share on

Middle East and Africa Infectious Disease Therapeutics Market Research Report – Segmented By Mode Of Treatment, Target Organism, Infection Type, Distribution Channels and Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis, Size, Share, Trends & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 1250
Pages: 132

MEA Infectious Disease Therapeutics Market Size (2021 to 2026)

The size of the Middle East and Africa Infectious Disease Therapeutics Market was worth USD 9.08 Billion in 2021 and estimated to reach 13.27 USD Billion by the end of 2026, registering a CAGR of 7.877% between 2021 to 2026.

Bacteria, fungi, viruses, and parasites are some of the microorganisms causing infectious diseases such as malaria, HIV, tuberculosis, influenza.

The MEA Infectious diseases therapeutics market is growing owing to the growing incidence of infectious diseases such as malaria, influenza, and other diseases in the region. Other factors, such as poor hygiene and sanitation in the environment, are driving the market for infectious disease therapeutics to grow.

In addition, the rising awareness about the prevention and management of the spread of infectious disease with the increase in the growth of disposable income in the urban areas further increases the growth of the market.

Moreover, the increase in the acceptance of advancement and innovation in the technology and the improving medical and healthcare infrastructure in the region, the rise in the accessibility to new advanced instruments is accelerating the growth of the infectious disease therapeutic market.

Furthermore, the rise in the initiatives and funding from government and non-government organizations in research activities to develop new products is expected to provide lucrative growth opportunities to the market. 

The rise in competition between major competitors for market expansion in the area through different market strategies such as new products, collaboration, acquisitions, and mergers will accelerate the growth of the infectious disease therapeutic market.

However, the market's development is limited by the expiration of patents for infectious disease drugs and a scarcity of skilled and trained experts to produce effective drugs. Additionally, concerns connected to adverse effects report the findings the medicines are impeding market expansion.

This research report on the Middle East and Africa Infectious Disease Therapeutics Market has been segmented & sub-segmented into the following categories:

By Mode of Treatment:

  • Drugs     
  • Vaccines 

By Target Organism:

  • Antibacterial     
  • Antifungal
  • Antiviral 
  • Antiparasite     
  • Others    

By Infection type:

  • Bacterial 
  • Viral     
  • Fungal   
  • Parasitic 
  • Others  

By Distribution Channels:

  • Hospitals 
  • Clinics    
  • Others     

By Country:

  • KSA
  • UAE
  • Israel
  • rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

The Middle East and Africa is projected to have significant growth in the infectious disease therapeutics market during the forecast period. The market growth is fuelled by the prevalence of infectious diseases such as malaria, HIV, influenza, and other diseases. However, key market players in the region are implementing various strategies for developing advanced products as well as raising awareness among the people regarding infectious diseases about its preventive and management measure are accelerates the market growth. 

UAE is estimated to show growth in the infectious disease therapeutics market in the coming years owing to the increase in the medical and healthcare infrastructure, and growing initiatives and fundings from the government and non-government in the research activities is boosting the market growth.

South Africa is also expected to have lucrative growth in the market. The market growth is fuelled by the increase in the competition between the players for expanding the therapeutic market. In South Africa, near the border areas, malaria transmission is more often in which more than 10 percent of the population are at the risk of contracting the disease in the area. It is due to the presence of efficient mosquitoes in the area and is a reliable high transmission. In the previous year, South Africa had 10,000 to 30,000 cases of malaria. As well as an increase in the prevalence of HIV in South Africa with 7.7 million people with a high prevalence rate of 20.4 percent, further are driving the market growth.

Key market participants dominating the MEA Infectious disease Therapeutics Market covered in this report are F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck & Co, Pfizer, Achillion Pharmaceuticals, Novartis, AbbVie, AstraZeneca, Auritec Pharmaceuticals, Bayer, Astellas Pharma, Chimerix Pharmaceuticals, Cubist, Eli Lilly, Isis Pharmaceuticals, Mitsubishi Tanabe Pharma, pSivida, Bristol-Myers Squibb and Sanofi.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                             

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 Mode of Treatment                

                                5.1.1 Introduction           

                                5.1.2 Drugs        

                                                5.1.2.1 Oral Administration

                                                5.1.2.2 Topical

                                                5.1.2.3 Injections

                                                5.1.2.4 Others

                                5.1.3 Vaccines  

                                5.1.4 Y-o-Y Growth Analysis, By Mode of treatment         

                                5.1.5 Market Attractiveness Analysis, By Mode of treatment        

                                5.1.6 Market Share Analysis, By Mode of treatment         

                5.2 Target Organism                      

                                5.2.1 Introduction           

                                5.2.2 Antibacterial          

                                5.2.3 Antifungal

                                5.2.4 Antiviral   

                                5.2.5 Antiparasite           

                                5.2.6 others       

                                5.2.7 Y-o-Y Growth Analysis, By Target Organism               

                                5.2.8 Market Attractiveness Analysis, By Target Organism             

                                5.2.9 Market Share Analysis, By Target Organism              

                5.3 Infection type                           

                                5.3.1 Introduction           

                                5.3.2 Bacterial   

                                5.3.3 Viral           

                                5.3.4 Fungal       

                                5.3.5 parasitic   

                                5.3.6 others       

                                5.3.7 Y-o-Y Growth Analysis, By Infection type    

                                5.3.8 Market Attractiveness Analysis, By Infection type  

                                5.3.9 Market Share Analysis, By Infection Type   

                5.4 Distribution Channels                            

                                5.4.1 Hospitals  

                                5.4.2 Clinics        

                                5.4.3 Others      

                                5.4.4 Y-o-Y Growth Analysis, By Distribution Channels     

                                5.4.5 Market Attractiveness Analysis, By Distribution Channels   

                                5.4.6 Market Share Analysis, By Distribution Channels    

6. Geographical Analysis                                              

                6.1 Introduction                              

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Mode of Treatment

                                                6.1.3.3 By Target organism

                                                6.1.3.4 By Infection Type

                                                6.1.3.5 By Distribution Channels

                                6.1.4 Market Attractiveness Analysis      

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Mode of Treatment

                                                6.1.4.3 By Target organism

                                                6.1.4.4 By Infection Type

                                                6.1.4.5 By Distribution Channels

                                6.1.5 Market Share Analysis        

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Mode of Treatment

                                                6.1.5.3 By Target organism

                                                6.1.5.4 By Infection Type

                                                6.1.5.5 By Distribution Channels

                6.2 Middle-East                                

                6.3 Africa                            

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 F. Hoffmann-La Roche                           

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Gilead Sciences                         

                8.3 GlaxoSmithKline                      

                8.4 Johnson & Johnson                 

                8.5 Merck & Co                

                8.6 Pfizer                            

                8.7 Achillion Pharmaceuticals                    

                8.8 Novartis                       

                8.9 Abbvie                         

                8.10 Astellas Pharma                     

                8.11 AstraZeneca                            

                8.12 Auritec Pharmaceuticals                     

                8.13 Bayer                          

                8.14 Bristol-Myers Squibb                           

                8.15 Chimerix Pharmaceuticals                 

                8.16 Cubist                         

                8.17 Eli Lilly                        

                8.18 Isis Pharmaceuticals                             

                8.19 pSivida                       

                8.20 Sanofi                         

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

 

  1. Middle East & Africa Infectious Disease Therapeutics Market, By Mode of treatment, From 2021 to 2026 (USD Billion)
  2. Middle East & Africa Drugs Market, By Region, From 2021 to 2026 (USD Billion)
  3. Middle East & Africa vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  4. Middle East & Africa Infectious Disease Therapeutics Market, By Target Organism, From 2021 to 2026 (USD Billion)
  5. Middle East & Africa Antibacterial Market, By Region, From 2021 to 2026 (USD Billion)
  6. Middle East & Africa Antifungal Market, By Region, From 2021 to 2026 (USD Billion)
  7. Middle East & Africa Antiviral Market, By Region, From 2021 to 2026 (USD Billion)
  8. Middle East & Africa Antiparasite Market, By Region, From 2021 to 2026 (USD Billion)
  9. Middle East & Africa Infectious Disease Therapeutics Market, By Infection Type, From 2021 to 2026 (USD Billion)
  10. Middle East & Africa Bacterial Market, By Region, From 2021 to 2026 (USD Billion)
  11. Middle East & Africa Viral Market, By Region, From 2021 to 2026 (USD Billion)
  12. Middle East & Africa Fungal Market, By Region, From 2021 to 2026 (USD Billion)
  13. Middle East & Africa Parasitic Market, By Region, From 2021 to 2026 (USD Billion)
  14. Middle East & Africa Infectious Disease Therapeutics Market, By Distribution Channels, From 2021 to 2026 (USD Billion)
  15. Middle East & Africa Hospitals Market, By Region, From 2021 to 2026 (USD Billion)
  16. Middle East & Africa Clinics Market, By Region, From 2021 to 2026 (USD Billion)
  17. Middle East Infectious Disease Therapeutics Market, By Mode of treatment, From 2021 to 2026 (USD Billion)
  18. Middle East Infectious Disease Therapeutics Market, By Target Organism, From 2021 to 2026 (USD Billion)
  19. Middle East Infectious Disease Therapeutics Market, By Infection Type, From 2021 to 2026 (USD Billion)
  20. Middle East Infectious Disease Therapeutics Market, By Distribution Channels, From 2021 to 2026 (USD Billion)
  21. Africa Infectious Disease Therapeutics Market, By Mode of treatment, From 2021 to 2026 (USD Billion)
  22. Africa Infectious Disease Therapeutics Market, By Target Organism, From 2021 to 2026 (USD Billion)
  23. Africa Infectious Disease Therapeutics Market, By Infection Type, From 2021 to 2026 (USD Billion)
  24. Africa Infectious Disease Therapeutics Market, By Distribution Channels, From 2021 to 2026 (USD Billion)
  25. Middle East & Africa Infectious disease Therapeutics Market, By Drugs, From 2021 to 2026 (USD Billion)
  26. Middle East & Africa Oral Administration Market, By Region, From 2021 to 2026 (USD Billion)
  27. Middle East & Africa Topical Market, By Region, From 2021 to 2026 (USD Billion)
  28. Middle East & Africa Injections Market, By Region, From 2021 to 2026 (USD Billion)
  29. Middle East Infectious disease Therapeutics Market, By Drugs, From 2021 to 2026 (USD Billion)
  30. Africa Infectious disease Therapeutics Market, By Drugs, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 2875

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample